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Summary
Background: Arylsulfatase A (ASA)-deficient mice are a model for the lysosomal storage disorder
metachromatic leukodystrophy. This lipidosis is characterised by the lysosomal accumulation of the
sphingolipid sulfatide. Storage of this lipid is associated with progressive demyelination. We have
mated ASA-deficient mice with mice heterozygous for a non-functional allele of UDP-
galactose:ceramide-galactosyltransferase (CGT). This deficiency is known to lead to a decreased
synthesis of galactosylceramide and sulfatide, which should reduce sulfatide storage and improve
pathology in ASA-deficient mice.
Results: ASA-/- CGT+/- mice, however, showed no detectable decrease in sulfatide storage.
Neuronal degeneration of cells in the spiral ganglion of the inner ear, however, was decreased.
Behavioural tests showed small but clear improvements of the phenotype in ASA-/- CGT+/- mice.
Conclusion: Thus the reduction of galactosylceramide and sulfatide biosynthesis by genetic means
overall causes modest improvements of pathology.
Background
Metachromatic leukodystrophy (MLD) is a lysosomal
storage disease of humans, which is characterised by pro-
gressive demyelination. The underlying defect is the defi-
ciency of arylsulfatase A (ASA), which results in the
lysosomal accumulation of the sphingolipid 3-O-sulfoga-
lactosylceramide (sulfatide) predominantly in brain, kid-
ney and bile ducts [1]. In the typical late infantile form of
the disease patients start to develop gait disturbances,
ataxia and paresis between the ages of 18 to 24 months.
The neurologic symptoms usually progress rapidly and
finally patients die in a decerebrated state. The disease is
currently untreatable. Since MLD naturally only occurs in
humans a mouse model was generated by targeted disrup-
tion of the ASA gene [2]. These animals store sulfatide in
the same tissues as humans, including oligodendrocytes,
Schwann cells and various neurons [2-4]. The accumula-
tion of sulfatide in the central nervous system steadily
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increases with progressing age of the animals. However,
the ASA-deficient mice have a mild phenotype, since they
do not show widespread demyelination in the central
nervous system typical for patients. Except for oli-
godendrocytes sulfatide is also stored in certain neurons,
which in some cases leads to neuronal degeneration. This
is particularly evident in the inner ear. In between 6 to 12
months of age neurons of the spiral ganglion of the inner
ear degenerate completely [5,6]. In addition, ASA-defi-
cient mice show a decrease of the axonal diameter in
peripheral nerves [2,7]. The mice develop progressive neu-
rological symptoms, which are, however, not lethal. In
summary, the pathological and behavioural studies per-
formed so far suggest that the animals resemble early
stages of human disease [2,3,8-10].
Sulfatide is synthesised by sulfation of its precursor galac-
tosylceramide which is formed from ceramide by catalysis
of the enzyme UDP-galactose:ceramide-galactosyltrans-
ferase (CGT). Mice deficient for this enzyme do not pro-
duce galactosylceramide nor sulfatide [11,12].
Surprisingly, they are still able to myelinate since they
compensatorily synthesise glucosylceramide [12]. They
develop various neurologic symptoms and die at the age
of 2 to 3 months [11-14]. Heterozygous littermates having
only one copy of the CGT gene were investigated up to the
age of three months. They do not show any pathological
phenotype but display reduced levels of galactosylcera-
mide as well as sulfatide [12,13]. In these studies galacto-
sylceramide was found to be reduced to about 70–80%
and sulfatide to about 80% of normal, respectively.
To investigate whether reduction of galactosylceramide
synthesis is an option to treat MLD, CGT-heterozygous
animals were mated with ASA-deficient mice to obtain
ASA-/- CGT+/- animals. The influence of CGT heterozy-
gosity on the phenotype of ASA-deficient mice was exam-
ined.
Results
Brain lipid analysis of ASA-deficient mice heterozygous for 
a non-functional CGT allele
To investigate whether a decrease in galactosylceramide
and sulfatide synthesis can improve the phenotype of
ASA-deficient mice we crossed ASA-/- with CGT+/- mice.
Genotypes of offspring at the ASA and CGT locus were
determined by PCR as described under material and
methods. Lipids were extracted from brains of mice with
different genotypes and galactosylceramide and sulfatide
were quantified by thin layer chromatography (see Figure
1). Compared to control animals (ASA+/+ CGT+/+) levels
of sulfatide were increased in ASA-deficient animals but
no significant difference was found between ASA-deficient
mice with CGT+/+ and CGT+/- genetic background.
Galactosylceramide levels are decreased in brains of MLD
patients and ASA-deficient mice. This was also found in
the mice investigated here and again no difference was
found between CGT+/+ and CGT+/- mice. Thus, the alter-
ation in CGT gene dosage has no obvious overall effect on
sulfatide accumulation and galactosylceramide reduction
in brains of ASA-deficient mice.
Pathology of ASA-deficient mice heterozygous for a non-
functional CGT allele
Beside the nervous system kidneys of ASA-deficient mice
show the highest amount of sulfatide storage material
[15]. The histochemical examination of the kidneys
revealed no differences between ASA-/- CGT +/- mice and
Lipid analysis Figure 1
Lipid analysis. Sulfatide (A) and galactosylceramide (B) lev-
els in whole brain extracts of ASA-deficient mice with one or 
two intact CGT genes and wild type controls. No significant 
difference between the ASA-deficient mice with different 
CGT backgrounds could be observed at all examined time 
points. Lipid concentrations are given in µmol per gram 
homogenized brain powder. Lipids were quantified by thin 
layer chromatography. The numbers of animals used for anal-
ysis (n) are given inside the columns. Error bars represent 
standard deviations of the mean values. **P ≤ 0.01 knock out 
against wild type by 1-way ANOVA; n.s.: not significant.Lipids in Health and Disease 2006, 5:21 http://www.lipidworld.com/content/5/1/21
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ASA-/- CGT+/+ mice, as far as the degree and topographic
distribution of sulfatide storage are concerned (results not
shown). In the nervous system the most impressive
degenerative alteration seen in ASA-deficient mice is the
neuronal cell loss in the spiral ganglion of the inner ear
starting 6 – 8 months after birth. At the age of 12 months
the majority of neurons is lost in ASA-deficient mice [5,6].
To examine whether the heterozygosity for CGT has any
influence on the pathology of ASA-deficient mice we
quantified the cell loss in the spiral ganglion of mice with
various genotypes. In these examinations ASA-deficient
mice bearing only one intact CGT gene showed a clear
improvement of pathology (see figure 2). The degenera-
tion of neurons observed in the spiral ganglion of ASA-
deficient mice was clearly mitigated in the CGT-hetero-
zygous mice. This improvement can easily be seen by light
microscopy (Fig. 2). We also quantified the number of
cells by counting cells present in an area of defined size.
This revealed a remarkable difference between ASA-/-
CGT+/+ and ASA-/- CGT+/- mice. In animals older than
12 month only 26% of cells had survived in the spiral gan-
glion of ASA-deficient mice when compared to wild-type,
whereas 57% were still structurally intact in mice bearing
only one intact CGT gene (Figure 2d).
Behavioural studies
ASA-deficient mice show various slowly progressing neu-
rologic symptoms. The animals are hyperactive, have
problems to stay on a rotating rod and show impairment
in the morris water maze [10]. In the latter, however,
impairments may be due to reduced neuromotor coordi-
nation capabilities rather than true learning deficits. To
examine whether behavioural impairments are improved
in ASA-/- CGT+/- mice, we performed various behavioural
tests with these animals. When compared to wild-type
and ASA-deficient mice no significant improvement in
cage activity, rotarod or open field testing could be
observed in ASA-deficient animals heterozygous for CGT.
Only the Dark-Light-transition box test – a test of explora-
tion and anxiety, but possibly less affected by the hyperac-
tivity of the animals – showed a significant improvement
in ASA-deficient mice bearing only one CGT allele (fig. 3).
Discussion
In recent years various approaches to treat lysosomal stor-
age diseases have been investigated. These include
enzyme replacement therapy, gene therapy and substrate
reduction therapy. Enzyme replacement therapy has been
approved as therapy for various lysosomal storage dis-
eases, such as Gaucher disease, Fabry disease, Pompe dis-
ease and certain kinds of mucopolysaccharidosis (for
reviews see [16-20]). A number of reports deal with gene
therapy approaches in animal models of lysosomal stor-
age diseases [21-25]. However, although some of these
studies show promising results the routine clinical appli-
cation is not feasible in foreseeable future. In contrast,
substrate reduction therapy has been shown to be a prom-
ising concept and is an approved therapy of some patient
with Gaucher type 1 disease [26-31]. Compared to
enzyme replacement, substrate reduction therapy may
offer advantages for diseases with central nervous system
involvement, because inhibition of synthesising enzymes
depends on small molecule competitive inhibitors, which
may be modified such that they can cross the blood brain
Loss of neurons from the spiral ganglion of the inner ear Figure 2
Loss of neurons from the spiral ganglion of the inner 
ear. Decalcified cochleae from mice of the indicated geno-
types were incubated with alcian blue for selective staining of 
sulfatides, post-fixed with osmium tetroxide and embedded 
in paraffin. a: ASA+/+ CGT+/+ mouse (age 18 months). 
The neuronal perikarya are densely packed and intermingled 
with myelinated fibres of the cochlear nerve. Alcianophilic 
(sulfatide rich) structures are absent from the ganglion. b: 
ASA-/- CGT+/+ mouse (age 17 months). The neurons 
(N) contain alcianophilic material and are greatly reduced in 
number. The other cells which are heavily laden with alciano-
philic material are macrophages (M) and Schwann cells (not 
labelled). c: ASA-/- CGT+/- mouse (age 17 months). 
The loss of neurons is less dramatic than in c, whereas the 
sulfatide storage in neurons and macrophages appears simi-
lar. Bar, 50 µm for all figures. d: Quantitative measure-
ment. Number of spiral ganglion perikarya per test area 
measuring 120 µm × 120 µm. Age of the deficient mice 14–
17 months. Values for wild-type mice at 10–18 months of age 
were taken from [6]. The numbers of animals used for analy-
sis (n) are given inside the columns. Error bars represent 
standard deviations of the mean values.**P ≤ 0.01 knock out 
against wild type by 1-way ANOVA.Lipids in Health and Disease 2006, 5:21 http://www.lipidworld.com/content/5/1/21
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barrier. In addition, treatment of hypercholesteremia with
inhibitors of HMG-CoA-Reductase has proven that inhibi-
tion of lipid synthesis is a valuable clinical option to
reduce levels of particular lipids [32,33]. The compound
N-butyldeoxynojirimycin has been shown to inhibit the
synthesis of glucosylceramide and is approved for therapy
of Gaucher disease in which glucosylceramide accumu-
lates [34]. Since glucosylceramide is also the precursor of
gangliosides it is also employed in the treatment of GM2
gangliosidosis. The possible benefits of such a therapy has
been demonstrated in animal models and clinical studies
are already performed [31,35-40].
Whereas globoid cell leukodystrophy (Krabbe disease) is
the result of defects in the degradation of galactosylcera-
mide, sulfatide accumulation leads to MLD. Thus, the
inhibition of either CGT or galactosylceramide sulfotrans-
ferase (CST) is therefore an option to reduce galactosylce-
ramide and/or sulfatide levels in these lysosomal storage
disorders. Galactosylceramide storing twitcher mice, a
model for Krabbe disease, show a decreased life span and
body weight, and they suffer from demyelination and var-
ious neurological symptoms [41-43]. To investigate the
possible benefits of reduction of galactosylceramide syn-
thesis for the treatment of Krabbe disease, twitcher mice
were mated with mice bearing a deficient CGT allele to
yield twitcher mice with only one copy of a functional
CGT allele. Although the amount of galactosylceramide
was not reduced in the CGT-heterozygous twitcher mice
these animals showed a moderate but significant
improvement of their phenotype [44].
In MLD sulfatide is the accumulating lipid, and patients
suffer from demyelination and devastating neurologic
symptoms [1]. Since the synthesis of sulfatide from cera-
mide is a two-step process both the enzymes involved –
the CGT and the CST – are possible targets for inhibition
of sulfatide synthesis. In contrast to glucosylceramide
transferase, inhibitors of CGT or CST are currently not
available. It was shown recently that mice bearing only
one functional copy of the CGT gene have reduced levels
of galactosylceramide as well as sulfatide [11,12]. There-
fore we mated these animals with ASA-deficient mice. In
the CGT-heterozygous ASA-deficient mice, however, the
overall amount of sulfatide in brain was not reduced. In
addition no effect on the reduction of galactosylceramide
in ASA-deficient mice was seen in the animals hetero-
zygous for CGT. This is in accordance with the results pre-
sented for CGT-heterozygous twichter mice [44]. Here
also no reduction of galactosylceramide was found. In this
study the authors interpreted this surprising results as
coincidental. They assumed that the expected reduction in
galactosylceramide is compensated by a prolonged sur-
vival of oligodendrocytes due to reduced galactosylcera-
mide synthesis. As a consequence of reduced synthesis
and preservation of oligodendrocytes the galactosylcera-
mide levels appeared unaltered.
Beside lysosomal storage of sulfatide in myelin forming
glia cells, examination of ASA-deficient mice has clearly
shown, that also a number of neurons store sulfatide [2-
4]. In neurons of the spiral ganglion this storage is accom-
panied with neuronal degeneration, whereas neuronal
storage without any cellular damage can be observed in
several nuclei of brainstem, diencephalon and spinal cord
[2,4]. Thus, the pathogenesis of this lysosomal storage dis-
order beside its glial certainly also has a neuronal compo-
nent. For the spiral ganglion we found that the
Behavioural analysis of ASA-deficient mice with one or two  intact CGT genes and wild type controls Figure 3
Behavioural analysis of ASA-deficient mice with one 
or two intact CGT genes and wild type controls. Wild 
type and ASA-deficient mice were tested like described. 
Whereas tests for cage activity (A) showed no improvement 
in ASA-deficient mice with only one intact CGT allele, the 
Dark-Light transition box test (B) showed a clear improve-
ment in these animals. The numbers of animals used for anal-
ysis (n) are given inside the columns. Error bars represent 
standard deviations of the mean values. *P ≤ 0.05 knock out 
against wild type by 1-way ANOVA; n.s.: not significant.Lipids in Health and Disease 2006, 5:21 http://www.lipidworld.com/content/5/1/21
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manipulation of galactosylceramide and sulfatide biosyn-
thesis leads to mitigation of neuronal degeneration,
although ganglion cells still do store sulfatides (Fig. 2c).
Former experiments have demonstrated that brain stem
auditory-evoked potentials correlate with the amounts of
neurons in the spiral ganglion [6]. Therefore we expect an
improvement of the deafness phenotype seen in ASA-defi-
cient mice. Unfortunately, due to the small number of
neurons in this ganglion, we are not able to determine the
extent of sulfatide storage at the cellular level, so that this
improvement cannot directly be correlated with the accu-
mulated amount of sulfatide.
Conclusion
The behavioural studies revealed only very selective
improvements in ASA-deficient CGT-heterozygous mice.
Thus, the phenotypic and pathologic improvements in
ASA-/- CGT+/- mice are significant but overall minor. If
extrapolated to the clinical situation they are certainly not
satisfactory. However, it should be taken into account that
the reduction of sulfatide biosynthesis in CGT+/- mice is
only around 20%. The results presented here suggest that
a far more efficient inhibition is necessary to achieve a
substantial positive clinical effect. Surprisingly, this slight
reduction is obviously already sufficient to mitigate the
neuronal degeneration in the ASA-deficient mice.
Methods
Chemicals
Silica gel 60 (230–400 mesh) and precoated HPTLC-
plates were obtained from Merck AG, Darmstadt, Ger-
many. The silica-gel plates used for TLC-ELISA were pre-
coated plastic sheets, Polygram R. Sil G, from Macherey-
Nagel, Düringen, Germany. Sulfatide and galactosylcera-
mide standards were isolated and characterised at the
Institute of Clinical Neuroscience, Goteborg University,
Sweden.
Generation of mice
Mice heterozygous for the CGT gene were a generous gift
of B. Popko [12]. For generation of CGT +/+ and CGT +/-
on wildtype and ASA-deficient background the CGT het-
erozygous (C57/Bl6) animals were bred with wildtype as
well as ASA-deficient (both 129ola). CGT +/+ and +/- lit-
termates on the different ASA backgrounds were used for
analysis.
For the genotyping of animals DNA of mouse tail tips was
analysed by PCR using the following primers: 5'-TGAC-
CAAGGCCTTGTTCCCAT-3', 5'-TAGGGTGGAAGTTAC-
CCTAGA-3', 5'-GGAGAGGCTATTCGGCTATGAC-3' for
ASA genotyping and 5'-CTCTCAGAAGGCAGAGACATT-
GCC-3', 5'-CATCCATAGGCTGGACCCATGAAC-3', 5'-
GGAGAGGCTATTCGGCTATGAC-3' for CGT genotyping;
The PCR program was as follows: initial denaturation at
94°C for 5 min, then 32 cycles 94°C 30 s, 56°C 60 s,
72°C 120 s.
For ASA PCR resulted in a 480 bp product for the wild-
type allele and a 1.2 kb for the knockout allele and for
CGT in a 558 bp and a 1.4 kb product, respectively.
Lipid extraction and isolation
Frozen brains were mortared under liquid nitrogen and
approximately 100 mg of the homogenised brain powder
was processed for lipid extraction with chloroform:meth-
anol:water, (C/M/W 4:8:3, by vol.) [45]. Phase partition
was performed in C/M/0.1 M KCl (10:5:2, by vol.). The
final lipid fraction, consisting of the lower phase, was
stored in C/M/W (60:30:4,5 by vol.) and aliquots of each
age were taken for sulfatide and galactosylceramide deter-
mination by densitometry after High Performance Thin
Layer Chromatography and orcinol visualisation [46].
Significance of differences between means was assessed by
1-way ANOVA.
Morphology
For the morphological examination animals 10 to 21
months of age were used. Some tissue samples of wild-
type mice were taken from previous experiments. Under
deep anaesthesia (intraperitoneal injection of tribro-
moethanol) the animals were killed by transcardial vascu-
lar perfusion with Bouin's mixture (diluted with
phosphate-buffered saline to 25% of the original for-
mula) or 6% glutaraldehyde in 0.1 M phosphate buffer
(pH 7.4). Temporal bones were removed from the skull
and decalcified with 4% EDTA [47]. Bones and thick slices
of kidneys were processed for selective staining of sulfati-
des. This was achieved by incubation (3 weeks) with the
cationic dye alcian blue (Alcec Blue, Aldrich, Steinheim,
Germany) in the presence of 0.3 M MgCl2 as described
[48]. The samples were then postfixed with 2% OsO4 for
3 hours and embedded in paraffin; sections (3–5 µm)
were mounted with DePeX without further staining. Mor-
phometric analysis of the spiral ganglion of the inner ear
was performed by counting the ganglion cells in a test area
measuring 120 µm × 120 µm. Significance of differences
between means was assessed by 1-way ANOVA.
Behavioural testing
Behavioural testings were performed as already described
[8].
For cage activity recording mice are on a 12/12 h dark-
light schedule (lights on at 8 AM, off at 8 PM). Standard
transparent mouse cages (16 × 22 cm2 bottom area; on
sawdust bedding) are placed between 3 infrared photo-
cells (2 along the short axis and 1 along the long axis of
the cage), and the number of beam crossings is recordedLipids in Health and Disease 2006, 5:21 http://www.lipidworld.com/content/5/1/21
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during a defined period using a lab-built programmable
counter. Single animals are placed in the recording cages
in the late afternoon (dusk phase of their activity), and
typically show an initial increase of exploratory activity
followed by relatively high nocturnal activity. Activity is
thus expressed as total beam crossings during the first 2 h
as well as during the total 16 h overnight recording (4 PM
through 8 AM).
Exploratory activity is assessed in the dark-light transition
box. The box consists of a large illuminated compartment
(55 × 73 cm2) and a smaller dark compartment (9 × 73
cm2) with four 4-cm holes, equally spaced in the dividing
wall to allow transition between these compartments.
Mice are first dark adapted for 1 h, and subsequently,
placed in the dark compartment of the box. Exploratory
activity is recorded for 10 min and expressed as the
amount of crossings of 2 photobeams parallel to the
dividing wall (beam 1: 1 cm from the wall; beam 2: 10 cm
from the wall).
Significance of differences between means was assessed by
1-way ANOVA.
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